Engineered immune cells take on deadly skin cancer
NCT ID NCT01955460
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 21 times
Summary
This early-phase study tested a new approach for people with advanced melanoma that has spread. Doctors took immune cells (T-cells) from patients, modified them in the lab to resist a tumor-blocking signal (TGF-beta), and returned them along with a drug (IL-2) to boost their activity. The goal was to see if this treatment was safe and could shrink tumors. The study involved 34 participants and focused on feasibility and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.